Dishman Carbogen Amcis Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i0eqwq0j70lhiipcj4w7xajl.pdf

Key Takeaways


The India Unlock

Harshil Dalal: "India is definitely, I would say, the growth in India is going to be one of the key strategies for us in order to increase the revenue at a group level, as well as improve the profitability significantly. Because historically, India had been doing close to about 35-40% operating margin for us. And that is kind of level that we would want to get back as quickly as possible."

Debt Restructuring & Interest Cost

Harshil Dalal: "if my revenue was in rupees, and if my subsidiaries were also not generating any revenues in Swiss francs, and also at the India stand-alone level, then I'm with you. But here, I have a lot of Swiss franc receivables, a lot of Swiss franc inflows that are coming in, which will be utilized to service the interest and the principal payment."

ADC & High-Margin Growth Drivers

Harshil Dalal: "The partnership is very tight. We host them on our site regularly. We go there to see them and to discuss the progress of the project."

French Facility Turnaround


CDMO Engine & Late-Phase Pipeline

Stephan Fritschi: "we are well-positioned for the future and I'm absolutely optimistic and confident that we're on the right track and we get more products and business in."

Margin Bridge & Below-the-Line Items


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated net interest costNot more than INR 100 croresFY27 full year
India stand-alone interest costNot more than INR 70-odd croresFY27 full year
Quarterly interest run-rateINR 30–35 crores per quarter or lowerFrom Q2 or Q3 FY27
India debt refinancing closeReplace INR ~800 cr high-cost debt with ~4% FX loanAround Q2 FY27
French facility revenueEUR 11–12 millionFY27
French facility EBITDA lossEUR 6 million (down from EUR 9 million)FY27
French facility breakevenEBITDA positiveFY28
ADC linker/payload revenueCHF 3 crores (FY27), CHF 4 crores (FY28)FY27 / FY28
Group EBITDA margin25%FY28
India top lineINR 500 crore-plusFY28
Effective tax rate~40% (FY27), ~30% (FY28), ~15–20% (~3 years)FY27 / FY28 / FY29+
Net debt reductionAt least CHF 1–1.5 crores (INR ~150 cr) per yearAnnual, ongoing
Revenue CAGRClose to ~15%Next 3 years
CDMO / marketable molecules mix85% / 15%Next 2–3 years

Key Metrics

MetricQ4 FY26
Revenue₹851 cr, +19% YoY from ₹716 cr in Q4 FY25
CDMO segment revenue₹690.8 cr, +21% YoY from ₹569 cr in Q4 FY25
Marketable molecules segment revenue₹160.5 cr, +9.3% YoY from ₹146.9 cr in Q4 FY25
EBITDA₹163 cr, 19.1% margin vs 23.9% in Q4 FY25
CDMO segment EBITDA margin18.7%, vs 23.9% in Q4 FY25, due to lower share of late Phase 3 deliveries
Marketable molecules segment EBITDA margin21.1%, driven by higher Vitamin D analog share and supplier cost optimization
Profit after tax₹21.7 cr
Full-year FY26 revenue₹2,932 cr, +8% YoY from ₹2,711 cr in FY25
Full-year FY26 EBITDA margin19.3%, +200 bps YoY from 17.3% in FY25
Full-year FY26 profit after tax₹97.4 cr, vs ₹3.2 cr in FY25
Full-year FY26 CDMO segment revenue₹2,441 cr, +6.5% YoY
Full-year FY26 marketable molecules segment revenue₹490.65 cr, +17% YoY from ₹418.5 cr in FY25
Full-year FY26 marketable molecules EBITDA margin18.8%, +940 bps YoY
Net debt (excl. lease liabilities)CHF 14.68 cr, down CHF 1.1 cr from CHF 15.76 cr at FY25 end
CapEx (full FY26)CHF 2.24 cr
ADC contribution to CDMO revenue (FY26)~25%
French facility revenue (FY26)€8 mn, with EBITDA loss of ~€9 mn; FY27 revenue expected €11-12 mn, loss ~€6 mn
India stand-alone debt~₹800 cr, average interest cost 10.5-11%; proposed ECB refinancing at ~4% to reduce interest cost
Effective tax rate guidance~40% for FY27, trending to ~30% in FY28 and 15-20% in ~3 years
Revenue CAGR target (next 3 years)~15%
EBITDA margin target25% by FY28